HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
Last updated: 2026-11-19 08:30:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Oculis Holding AG (OCS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $7.40, with a market capitalization of $418.42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.78 to $34.48. This page covers its latest market performance, valuation, price trends and company information.
$418.42M | |
$7.56 | |
$7.81 | |
$7.22 | |
$7.51 | |
273.11K | |
272.37K | |
-- | |
$34.48 | |
$6.78 | |
-- | |
2026-09-30 |
Oculis Holding AG (OCS) last closed at $7.40 as of 2026-11-19 00:31:00, down 1.60% ($0.12) from the previous close of $7.51.
During the latest regular trading session, OCS traded between $7.22 and $7.81, with a volume of 273.11K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Oculis Holding AG (OCS) moved from $7.59 to $7.40, representing a decline of 2.52% ($0.19).
The stock traded between $7.09 and $8.21 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 248.57 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2.2%
OCS is currently trading at $7.40, placing it 2.2% of the way from its 52-week low of $6.78 to its 52-week high of $34.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
| Employees | 67 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Oculis Holding AG and OCS stock.
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic
Oculis Holding AG (OCS) has a mean analyst price target of $36.90, suggesting 384.9% upside potential from its current $7.61 price. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions over the past 30 days. However, the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions, as they often reflect business incentives rather than realistic valuations.
Eligible investors can buy real shares of Oculis Holding AG (OCS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to OCS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between OCS shares and USD.
OCS Shares to USD
1.00 OCS shares = 7.399 USD
Calculations are estimates based on the latest available price and are for reference only.